← brief for 2026-08-15 · Slowing decline

Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?

Article B Peer reviewed Small trial

Key takeaways

This small trial (25 patients, 12 weeks) found that combining GLP-1 RAs with SGLT2is reduced risk of heart failure and kidney decline. However, it did not reach statistical significance for these outcomes.

Who did this work

Medeiros R · Mendes I

Source

Article · PubMed, the drug frontier · 2026 Jul 15
https://pubmed.ncbi.nlm.nih.gov/42602910/